CSL Vifor Managed Access Programs
In circumstances where patients have exhausted approved treatment options and are not eligible for clinical trials, CSL Vifor supports early access to investigational drugs via Managed Access Programs which describe how healthcare professionals can submit requests for access to investigational drugs on behalf of the patients in their care.
Learn More About These ProgramsSearch Results
179 results found-
LIVING WITH IRON DEFICIENCY SINCE THE AGE OF 16
https://www.csl.com/patients-public-health/iron-deficiency/iron-deficiency-patient-stories/iron-deficiency-andy -
ST. GALLEN, SWITZERLAND, March 19, 2024 / PRNewswire / -- CSL Vifor today announced that Health Canada has authorized Ferinject (ferric carboxymaltose) for the intravenous (IV) treatment of iron deficiency anemia in adult and pediatric patients one year of age and older when oral iron preparations are not tolerated or are ineffective, as well as for the treatment of iron deficiency in adult patients with heart failure and New York Heart Association (NYHA) class II/III* 1 to improve exercise capacity.
https://newsroom.csl.com/2024-03-19-Ferinject-R-approved-by-Health-Canada-for-the-treatment-of-iron-deficiency-anemia-in-adult-and-pediatric-patients-and-iron-deficiency-in-adult-patients-with-heart-failure -
CSL is an Equal Opportunity Employer. If you are an individual with a disability and need a reasonable accommodation for any part of the application process, please let us know.
https://www.csl.com/careers/eeo-statement -
Answers to the most frequently asked questions about Clinical Trials.
https://www.csl.com/research-and-development/clinical-studies/clinical-studies-faqs -
CIDP can occur at any age and is more common in men than in women.
https://newsroom.csl.com/2024-01-03-CSL-Behring-Announces-Availability-of-Hizentra-R-Immune-Globulin-Subcutaneous-Human-20-Liquid-10g-Prefilled-Syringe -
To promote medical and scientific research, we share data from CSL Vifor sponsored clinical studies on products with approved indications in both the EU and the USA.
https://www.csl.com/research-and-development/awards-grants-and-initiatives/csl-vifor-iis -
CSL strives to embed diversity, equity and inclusion in everything we do, including talent acquisition, employee support and community engagement.
https://www.csl.com/sustainability/promising-futures/inclusion-and-belonging -
USOTC:CSLLY) today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending granting a marketing authorization for garadacimab as a once-monthly prophylactic treatment for hereditary angioedema (HAE) in adult and adolescent patients aged 12 years and older.
https://newsroom.csl.com/2024-12-13-CSL-Receives-Positive-CHMP-Opinion-for-Garadacimab-in-Hereditary-Angioedema-HAE -
2 During the COVID-19 pandemic, there have been over 95 million confirmed cases of the disease and over 1 million deaths in the U.S. 3 The Centers for Disease Control and Prevention (CDC) recommends COVID-19 vaccination for everyone ages six months and older in the U.S. for the prevention of COVID-19.
https://newsroom.csl.com/2022-12-12-CSL-Announces-Closing-of-Global-Collaboration-and-Licensing-Agreement-with-Arcturus-Therapeutics -
Patients eligible for enrollment include adults at least 18 years of age who experienced a type 1 (spontaneous) heart attack, along with multivessel coronary artery disease and the presence of established CV risk factors, including treatment for type 2 diabetes or at least two of the following:
https://newsroom.csl.com/2020-11-05-CSL-Behring-Publishes-Design-for-First-Ever-Outcomes-Study-of-ApoA-I-to-Reduce-Risk-of-Cardiovascular-Events-in-Heart-Attack-Patients